International journal of clinical pharmacology and therapeutics, 2016-07, Vol.54 (7), p.498-501
2016
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- FAAH inhibitors in the limelight, but regrettably
- Ist Teil von
- International journal of clinical pharmacology and therapeutics, 2016-07, Vol.54 (7), p.498-501
- Ort / Verlag
- Germany
- Erscheinungsjahr
- 2016
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- This short review focuses on the recent drug development of FAAH inhibitors, as recent serious adverse events have been reported in a phase I study with a compound of this class. The authors overview the potential interest in targeting FAAH inhibition, the current programs, and the available information on the recent dramatic events.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0946-1965DOI: 10.5414/cp202687Titel-ID: cdi_pubmed_primary_27191771
- Format
- –
- Schlagworte
- Amidohydrolases - antagonists & inhibitors, Amidohydrolases - metabolism, Brain - drug effects, Brain - physiopathology, Brain Death, Brain Diseases - chemically induced, Brain Diseases - mortality, Brain Diseases - physiopathology, Clinical Trials, Phase I as Topic, Coma - chemically induced, Coma - mortality, Dose-Response Relationship, Drug, Drug Interactions, Early Termination of Clinical Trials, Enzyme Inhibitors - adverse effects, Humans, Risk Assessment, Risk Factors, Treatment Outcome